Coronavirus: EU will sign supply deal for Pfizer COVID-19 vaccine

Published: Updated:

The European Union is about to sign a contract for millions of doses of the COVID-19 vaccine being developed by Pfizer and BioNTech, a prominent EU lawmaker said on Monday.

The remark was made hours after the two companies said their experimental vaccine was more than 90 percent effective, in what could be a major victory in the fight against the coronavirus pandemic.

Read the latest updates in our dedicated coronavirus section.

The European Commission, which is negotiating with vaccine makers on behalf of EU states, said in September it had concluded exploratory talks with US pharmaceutical giant Pfizer and its German partner BioNTech over the supply of 200 million doses of their potential COVID-19 shot.

However, a deal has not been announced yet.

“According to my information, the respective contract is about to be signed,” said Peter Liese, the EU lawmaker who leads on health matters for the largest grouping in the European Parliament, comprising center-right lawmakers.

“There is an agreement that Europeans will be provided with hundreds of millions of vaccines,” he added in an emailed statement.

A spokesman for the Commission declined to comment on whether Pfizer’s announcement on the efficacy of its vaccine would speed up the signature of a supply deal.

The Commission has said previously that the 27 EU states could also have an option to order another 100 million doses of the Pfizer/BioNTech vaccine.

The EU has already signed supply deals with AstraZeneca , Sanofi and Johnson & Johnson for their potential COVID-19 shots.

The US, Japan and Britain have already announced supply deals with Pfizer.

Read More:

Coronavirus: Biden welcomes Pfizer vaccine news, warns precautions still needed

Coronavirus: UK expects to receive 10 mln doses of Pfizer COVID-19 vaccine in 2020

Coronavirus: Pfizer says COVID-19 vaccine 90 pct effective in phase 3 trials

Top Content Trending